Amundi Cuts Position in IDEXX Laboratories, Inc. $IDXX

Amundi trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 569,725 shares of the company's stock after selling 41,054 shares during the period. Amundi owned approximately 0.72% of IDEXX Laboratories worth $299,926,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. SHP Wealth Management purchased a new position in IDEXX Laboratories in the fourth quarter worth about $26,000. Virtus Advisers LLC bought a new stake in IDEXX Laboratories during the third quarter worth approximately $26,000. J.Safra Asset Management Corp purchased a new stake in IDEXX Laboratories during the second quarter valued at approximately $25,000. Elevation Wealth Partners LLC raised its position in IDEXX Laboratories by 188.2% during the second quarter. Elevation Wealth Partners LLC now owns 49 shares of the company's stock valued at $26,000 after purchasing an additional 32 shares during the period. Finally, Wormser Freres Gestion lifted its stake in shares of IDEXX Laboratories by 671.4% in the 4th quarter. Wormser Freres Gestion now owns 54 shares of the company's stock valued at $37,000 after purchasing an additional 47 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $535.38 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. The stock has a market cap of $42.18 billion, a price-to-earnings ratio of 37.65, a price-to-earnings-growth ratio of 2.86 and a beta of 1.54. The firm has a 50-day moving average of $558.25 and a two-hundred day moving average of $569.41. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.20 billion. During the same period last year, the company posted $3.50 earnings per share. The company's quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on IDXX shares. Barclays cut their target price on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 11th. Citigroup raised their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Weiss Ratings cut shares of IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. UBS Group increased their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $747.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.